Eye­Point and Rally­bio shake hands on col­lab­o­ra­tion; Sh­iono­gi ex­pects bil­lions for Covid an­tivi­ral pill — re­port

Eye­Point Phar­ma­ceu­ti­cals and Rally­bio will be en­ter­ing in­to a part­ner­ship.

The deal will look at the de­liv­ery of Rally­bio’s C5 in­hibitor us­ing Eye­Point’s tech for in­traoc­u­lar drug de­liv­ery, dubbed Durasert. The re­search will fo­cus on ge­o­graph­ic at­ro­phy, an ad­vanced form of mac­u­lar de­gen­er­a­tion that can even­tu­al­ly lead to vi­sion loss.

Both com­pa­nies al­so in­tend to ex­pand up­on the col­lab­o­ra­tion fol­low­ing the ini­tial re­search work. How­ev­er, no fi­nan­cial de­tails have been giv­en yet. In a re­lease, Rally­bio CEO Stephen Uden said that the use of C5 in­hibitors has al­ready shown “great promise.” While Jay Duk­er, pres­i­dent and COO of Eye­Point, said that the col­lab­o­ra­tion hopes to use the tech­nol­o­gy to pro­vide a more “de­sir­able op­tion” for pa­tients — as the cur­rent ther­a­py is in­ject­ed every one to two months.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN